We are live on ! Find out more
SLS icon

SELLAS Life Sciences
SLS

14 hedge funds and large institutions have $2.1M invested in SELLAS Life Sciences in 2018 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 0 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,345% more call options, than puts

Call options by funds: $489K | Put options by funds: $11K

1% more capital invested

Capital invested by funds: $2.07M → $2.1M (+$24.5K)

0.01% less ownership

Funds ownership: 0.2% → 0.18% (-0.01%)

13% less funds holding

Funds holding: 16 → 14 (-2)

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

Holders
14
Holders Change
-2
Holders Change %
-12.5%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
6
Reduced
–
Closed
5
Calls
$489K
Puts
$11K
Net Calls
+$478K
Net Calls Change
+$12K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$1.09M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$567K
3
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$54.8K
4
BlackRock
BlackRock
New York
+$43.3K
5
UBS Group
UBS Group
Switzerland
+$6.58K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$1.07M
2
APA
American Portfolios Advisors
New York
-$1.92K

SLS Hedge Fund Activity: Q2 2018 in Review

14 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in SELLAS Life Sciences (SLS) for Q2 2018, worth a combined $2.1M — up 1.2% from $2.07M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of SLS and 3 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 6 added.

The largest buyer was Renaissance Technologies, adding an estimated $1.09M. The largest seller was Sabby Management, exiting entirely with an estimated $1.07M sold.

  • 14 institutional investors held SELLAS Life Sciences (SLS) as of Q2 2018, down from 16 in Q1 2018.
  • Funds reported $2.1M of SELLAS Life Sciences stock for Q2 2018, up 1.2% quarter-over-quarter.
  • 3 funds opened new SELLAS Life Sciences positions in Q2 2018 and 5 closed out, a net change of -2 holders.
  • The largest SELLAS Life Sciences buyer in Q2 2018 was Renaissance Technologies, an estimated $1.09M added.
  • The largest SELLAS Life Sciences seller in Q2 2018 was Sabby Management, an estimated $1.07M sold.

Based on aggregated 13F filings for Q2 2018.